Currently, the treatment of advanced malignant melanoma made use of immuno-therapy with PD-1 and CTLA-4 inhibitors and, for melanomas harboring BRAF mutation, also, of target therapy with BRAF and MEK inhibitors. This evidence concerns the gene CTLA4 and melanoma.